The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial

Authors:

Abstract
No abstract available
Funding Information
  • Medigen Vaccine Biologics Corporation

This publication has 31 references indexed in Scilit: